MX2009001494A - 2-aminobenzoxazol carboxamidas como moduladores 5ht3. - Google Patents

2-aminobenzoxazol carboxamidas como moduladores 5ht3.

Info

Publication number
MX2009001494A
MX2009001494A MX2009001494A MX2009001494A MX2009001494A MX 2009001494 A MX2009001494 A MX 2009001494A MX 2009001494 A MX2009001494 A MX 2009001494A MX 2009001494 A MX2009001494 A MX 2009001494A MX 2009001494 A MX2009001494 A MX 2009001494A
Authority
MX
Mexico
Prior art keywords
aminobenzoxazole
carboxamides
modulators
compounds
ibs
Prior art date
Application number
MX2009001494A
Other languages
English (en)
Inventor
David J Fairfax
Zhicai Yang
Original Assignee
Albany Molecular Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Molecular Res Inc filed Critical Albany Molecular Res Inc
Publication of MX2009001494A publication Critical patent/MX2009001494A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Los compuestos de la fórmula (I), (II), (III) se describen como inhibidores de 5-HT3. Los compuestos son útiles en el tratamiento de CINV, IBS-D y otras enfermedades y afecciones.
MX2009001494A 2006-08-07 2007-08-07 2-aminobenzoxazol carboxamidas como moduladores 5ht3. MX2009001494A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82164606P 2006-08-07 2006-08-07
PCT/US2007/075378 WO2008019372A2 (en) 2006-08-07 2007-08-07 2-aminobenzoxazole carboxamides as 5ht3 modulators

Publications (1)

Publication Number Publication Date
MX2009001494A true MX2009001494A (es) 2009-04-23

Family

ID=38686790

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001494A MX2009001494A (es) 2006-08-07 2007-08-07 2-aminobenzoxazol carboxamidas como moduladores 5ht3.

Country Status (14)

Country Link
US (1) US7863271B2 (es)
EP (1) EP2061460A2 (es)
JP (1) JP5512268B2 (es)
KR (1) KR101417159B1 (es)
CN (1) CN101528225B (es)
AU (1) AU2007281678B2 (es)
BR (1) BRPI0716069A2 (es)
CA (1) CA2660349A1 (es)
IL (1) IL196949A (es)
MX (1) MX2009001494A (es)
NO (1) NO20090994L (es)
NZ (1) NZ574756A (es)
RU (1) RU2448105C2 (es)
WO (1) WO2008019372A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019372A2 (en) 2006-08-07 2008-02-14 Albany Molecular Research, Inc. 2-aminobenzoxazole carboxamides as 5ht3 modulators
EP2254884B1 (en) * 2008-02-15 2013-05-01 F. Hoffmann-La Roche AG 3-alkyl-piperazine derivatives and uses thereof
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
KR101653707B1 (ko) 2008-05-29 2016-09-02 알바니 몰레큘라 리써치, 인크. 5-ｈｔ3 수용체 조절제, 이의 제조 방법, 및 그의 용도
WO2010048514A1 (en) * 2008-10-23 2010-04-29 Albany Molecular Research, Inc. Synthesis of 2-aminobenzoxazole compounds
CA2767233A1 (en) 2009-07-14 2011-01-20 Albany Molecular Research, Inc. 5-ht3 receptor modulators, methods of making, and use thereof
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
RU2560729C2 (ru) * 2010-01-11 2015-08-20 АСТРАЕА ТЕРАПЕУТИКС, ЭлЭлСи Модуляторы никотиновых ацетилхолиновых рецепторов
DK2616460T3 (en) * 2010-09-13 2016-01-18 Otsuka Pharma Co Ltd HETEROCYCLIC COMPOUNDS FOR TREATMENT OR PREVENTION OF DISEASES CAUSED BY decreased neurotransmission of serotonin, norepinephrine or dopamine
JP6415982B2 (ja) * 2012-03-12 2018-10-31 大塚製薬株式会社 複素環化合物
JPWO2014051055A1 (ja) * 2012-09-28 2016-08-22 東レ株式会社 キヌクリジンウレア誘導体及びその医薬用途
CN103113321B (zh) * 2013-02-27 2015-02-18 南通大学 2-(甲硫基)苯并[d]噁唑-5-羧酸及其制备方法
US9890142B2 (en) 2013-07-10 2018-02-13 Meiji Seika Pharma Co., Ltd. PDE4 inhibitor
WO2015068744A1 (ja) 2013-11-08 2015-05-14 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
BR112019010571A2 (pt) * 2016-12-26 2019-09-17 Meiji Seika Pharma Co Ltd composto e sal farmacologicamente aceitável do mesmo
EP3774742A1 (en) 2018-04-06 2021-02-17 H. Lundbeck A/S Process for the preparation of 2,2-dimethylpiperazine
WO2023287241A1 (ko) * 2021-07-15 2023-01-19 주식회사 휴사이온 신규한 벤즈옥사졸아민 유도체 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482653A (en) * 1989-05-30 1996-01-09 Merck Patent Gesellschaft Mit Beschrankter Haftung Fluoro-chloro-benzene derivatives
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
JP3193560B2 (ja) * 1993-04-16 2001-07-30 明治製菓株式会社 新規ベンゾオキサゾール誘導体
WO1998047481A1 (en) * 1997-04-18 1998-10-29 Janssen Pharmaceutica N.V. Use of 5ht3 antagonists for promoting intestinal lavage
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
BR0213760A (pt) 2001-10-26 2004-10-19 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
EE05516B1 (et) * 2002-09-25 2012-02-15 Memory@Pharmaceuticals@Corporation Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine
MX2007010063A (es) * 2005-02-17 2008-01-16 Albany Molecular Res Inc Benzoxazol-carboxamidas para el tratamiento de la naucea y el vomito inducidos por quimioterapia y sindrome del intestino irritable con diarrea predominante.
WO2008019372A2 (en) 2006-08-07 2008-02-14 Albany Molecular Research, Inc. 2-aminobenzoxazole carboxamides as 5ht3 modulators
WO2008019363A2 (en) 2006-08-07 2008-02-14 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5ht3 modulators
KR101653707B1 (ko) * 2008-05-29 2016-09-02 알바니 몰레큘라 리써치, 인크. 5-ｈｔ3 수용체 조절제, 이의 제조 방법, 및 그의 용도

Also Published As

Publication number Publication date
AU2007281678A1 (en) 2008-02-14
WO2008019372A2 (en) 2008-02-14
KR20090038034A (ko) 2009-04-17
US7863271B2 (en) 2011-01-04
CN101528225B (zh) 2013-07-17
CN101528225A (zh) 2009-09-09
WO2008019372A3 (en) 2008-04-17
US20080255114A1 (en) 2008-10-16
BRPI0716069A2 (pt) 2013-09-17
NO20090994L (no) 2009-05-04
KR101417159B1 (ko) 2014-07-16
JP2010500368A (ja) 2010-01-07
CA2660349A1 (en) 2008-02-14
IL196949A0 (en) 2009-11-18
AU2007281678B2 (en) 2012-08-02
EP2061460A2 (en) 2009-05-27
IL196949A (en) 2013-11-28
RU2009108327A (ru) 2010-09-20
JP5512268B2 (ja) 2014-06-04
NZ574756A (en) 2011-03-31
RU2448105C2 (ru) 2012-04-20

Similar Documents

Publication Publication Date Title
MX2009001494A (es) 2-aminobenzoxazol carboxamidas como moduladores 5ht3.
WO2008019363A3 (en) 2-alkylbenzoxazole carboxamides as 5ht3 modulators
MX336381B (es) Boronatos como inhibidores de arginasa.
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
MX2010009765A (es) Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
GEP20125652B (en) cMET INHIBITORS
EA201100424A1 (ru) Новые ингибиторы
MX353257B (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2009111676A3 (en) Boron-containing small molecules as anti-inflammatory agents
UA104731C2 (ru) Ингибиторы р38 мар-киназ
WO2009117676A3 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
NZ589844A (en) Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
EA201170521A1 (ru) Новые соединения
WO2006081252A3 (en) Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
GEP20125511B (en) Mapk/erk kinase inhibitors
MX2009011205A (es) Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide.
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration